keyword
https://read.qxmd.com/read/38644084/prevalence-of-irritable-bowel-syndrome-and-other-functional-gastrointestinal-disorders-in-uruguay
#1
JOURNAL ARTICLE
V Guido, Y Pontet, V López, C Olano
INTRODUCTION AND AIMS: Irritable bowel syndrome (IBS) is one of the most frequent functional gastrointestinal disorders. Prevalence worldwide is estimated at 11%. There is little information on the prevalence of the other functional bowel disorders (FBDs). Our aim was to establish the prevalence of IBS and other FBDs according to the Rome IV criteria, in Uruguay. MATERIALS AND METHODS: An observational, population-based prevalence study was conducted. Data were collected through an online questionnaire, utilizing the Rome IV criteria...
April 20, 2024: Revista de Gastroenterología de México
https://read.qxmd.com/read/38643935/rome-iii-criteria-capture-higher-irritable-bowel-syndrome-snp-heritability-and-highlight-a-novel-genetic-link-with-cardiovascular-traits
#2
JOURNAL ARTICLE
Leticia Camargo Tavares, Esteban Alexander Lopera-Maya, Ferdinando Bonfiglio, Tenghao Zheng, Trishla Sinha, Francine Zanchetta Marques, Alexandra Zhernakova, Serena Sanna, Mauro D'Amato
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) shows genetic predisposition, and large-scale genome-wide association studies (GWAS) are emerging, based on heterogeneous disease definitions. We aimed at investigating the genetic architecture of IBS defined according to gold-standard Rome Criteria. METHODS: We conducted GWAS meta-analyses of Rome III IBS and its subtypes in 24,735 IBS cases and 77,149 asymptomatic controls from two independent European cohorts (UK Biobank and Lifelines)...
April 18, 2024: Cellular and Molecular Gastroenterology and Hepatology
https://read.qxmd.com/read/38617992/an-overview-of-the-effects-of-tenapanor-on-visceral-hypersensitivity-in-the-treatment-of-irritable-bowel-syndrome-with-constipation
#3
REVIEW
Prashant Singh, Gregory S Sayuk, David P Rosenbaum, Susan Edelstein, Kenji Kozuka, Lin Chang
BACKGROUND: Patients with irritable bowel syndrome with constipation (IBS-C) experience persistent abdominal pain, a common symptom leading to greater healthcare utilization and reports of treatment non-response. Clinically significant improvements in abdominal pain were observed in clinical trials of tenapanor, a first-in-class inhibitor of sodium/hydrogen exchanger isoform 3 (NHE3), for the treatment of IBS-C in adults. AIM: This narrative review reports the current knowledge about visceral hypersensitivity as a mechanism for abdominal pain in patients with IBS-C and explores the published evidence for hypothesized mechanisms by which tenapanor may reduce visceral hypersensitivity leading to the observed clinical response of decreased abdominal pain...
2024: Clinical and Experimental Gastroenterology
https://read.qxmd.com/read/38609737/fecal-calprotectin-levels-in-patients-with-non-celiac-wheat-sensitivity-a-proof-of-concept
#4
JOURNAL ARTICLE
Aurelio Seidita, Alessandra Giuliano, Maurizio Soresi, Marta Chiavetta, Emilio Nardi, Giuseppe Mogavero, Giulio Giannone, Antonio Carroccio, Pasquale Mansueto
Some data suggest the existence of intestinal inflammation in patients with non-celiac wheat sensitivity (NCWS). We aimed to verify whether fecal calprotectin (FCP), a marker of intestinal inflammation, could be used to confirm this inflammatory status and to test its diagnostic performance in differentiating NCWS from irritable bowel syndrome/functional dyspepsia (IBS/FD). We conducted a multicenter study, comparing NCWS patients, diagnosed by a double-blind placebo-controlled wheat challenge, with IBS/FD subjects...
April 12, 2024: Internal and Emergency Medicine
https://read.qxmd.com/read/38606696/prevalence-of-extra-intestinal-symptoms-according-to-irritable-bowel-syndrome-subtype
#5
JOURNAL ARTICLE
Facundo Pereyra, Luis María Bustos Fernández, Francisco Schlottmann, Rafael Zamora, Agustina Marconi, Leandro Steinberg, Lisandro Pereyra
BACKGROUND: Irritable bowel syndrome (IBS) is a functional disorder commonly associated with extra-intestinal symptoms. However, the prevalence of these symptoms according to IBS subtype is not well established. AIM: To compare the prevalence of extra-intestinal symptoms among patients with different subtypes of IBS. METHODS: A descriptive cross-sectional study including patients with IBS according to Rome IV criteria was performed between July 2022 and April 2023...
April 12, 2024: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://read.qxmd.com/read/38594429/plecanatide-improves-abdominal-bloating-and-bowel-symptoms-of-irritable-bowel-syndrome-with-constipation
#6
JOURNAL ARTICLE
Darren M Brenner, Amol Sharma, Satish S C Rao, Adam P Laitman, Zeev Heimanson, Christopher Allen, Gregory S Sayuk
BACKGROUND: Bloating is a bothersome symptom in irritable bowel syndrome with constipation (IBS-C). AIM: To evaluate plecanatide efficacy in patients with IBS-C stratified by bloating intensity. METHODS: Pooled phase 3 data (2 randomized, controlled IBS-C trials) from adults treated with plecanatide 3 mg or placebo for 12 weeks were analyzed. Patients were stratified post-hoc by baseline bloating severity (11-point scale: mild [≤ 5] and moderate-to-severe [> 5])...
April 9, 2024: Digestive Diseases and Sciences
https://read.qxmd.com/read/38590140/review-article-a-practical-approach-to-persistent-gastrointestinal-symptoms-in-inflammatory-bowel-disease-in-remission
#7
REVIEW
Arta Aliu, Daan H C A Bosch, Daniel Keszthelyi, Ashkan Rezazadeh Ardabili, Jean-Frederic Colombel, Rachel Sawyer, Hans Törnblom, Ailsa Hart, Daisy M A E Jonkers, Marieke J Pierik, Zlatan Mujagic
BACKGROUND: Persistent gastrointestinal symptoms are prevalent in adult patients with inflammatory bowel disease (IBD), even when endoscopic remission is reached. These symptoms can have profound negative effects on the quality of life of affected patients and can be difficult to treat. They may be caused by IBD-related complications or comorbid disorders, but they can also be explained by irritable bowel syndrome (IBS)-like symptoms. AIMS: To provide a practical step-by-step guide to diagnose and treat persistent gastrointestinal symptoms in patients with IBD in remission via a personalised approach...
April 8, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38566874/role-of-calprotectin-il-6-and-crp-in-distinguishing-between-inflammatory-bowel-disease-and-diarrhea-predominant-irritable-bowel-syndrome
#8
JOURNAL ARTICLE
Bui-Thi Thu Huong, Nguyen Minh Hien, Nguyen Tien Dung, Dao Minh Quang, Nguyen Thanh Vinh, Tran Thanh Tu, Tran Khanh Chi, Le-Thi Bich Phuong, Nguyen-Thi Nhan
BACKGROUND: The early establishment of prophylaxis and immediate administration of anticoagulant therapy upon the diagnosis of venous thromboembolism should be the treatment objectives in these patients. OBJECTIVE: The study aimed to determine the optimal cut-off point of Calprotectin, IL-6 (interleukin-6), CRP (C reactive protein) to differentiate UC, IBS-D. METHODS: A cross-sectional descriptive study of 335 individuals ≥15 years old was performed, including 31 healthy controls, 215 with IBS-D, 71 diagnosed with UC, and 18 diagnosed with CD...
2024: Medical Archives
https://read.qxmd.com/read/38527650/clostridioides-difficile-infection-promotes-gastrointestinal-dysfunction-in-human-and-mice-post-acute-phase-of-the-disease
#9
JOURNAL ARTICLE
Deiziane V S Costa, Nathalie V Pham, Andrea V Loureiro, Suemin E Yang, Brian W Behm, Cirle A Warren
OBJECTIVES: In the US, Clostridioides difficile (C. difficile) infection (CDI) is the 8th leading cause for hospital readmission and 7th for mortality among all gastrointestinal (GI) disorders. Here, we investigated GI dysfunction post-CDI in human and mice post-acute infection. MATERIALS AND METHODS: From March 2020 to July 2021, we reviewed the clinical records of 67 patients referred to the UVA Complicated C. difficile clinic for fecal microbiota transplantation (FMT) eligibility...
March 23, 2024: Anaerobe
https://read.qxmd.com/read/38504394/safety-and-efficacy-of-linaclotide-in-children-aged-7-17-years-with-irritable-bowel-syndrome-with-constipation
#10
JOURNAL ARTICLE
Carlo Di Lorenzo, Samuel Nurko, Jeffrey S Hyams, Gerardo Rodriguez-Araujo, Valentina Shakhnovich, Miguel Saps, Michael Simon
OBJECTIVES: Linaclotide, a guanylate cyclase-C agonist, was recently approved in the United States for the treatment of children 6-17 years old with functional constipation. This study evaluated the safety and efficacy of various linaclotide doses in children 7-17 years old with irritable bowel syndrome with constipation (IBS-C). METHODS: In this 4-week, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study, children with IBS-C were randomized to once-daily placebo or linaclotide (Dose A: 18 or 36 µg, B: 36 or 72 µg, and C: 72 µg or 145 µg, or 290 µg); those aged 7-11 years in a 1:1:1:1 allocation based on weight (18 to <35 kg:18 µg, 36 µg, or 72 µg; or ≥35 kg: 36 µg, 72 µg, or 145 µg), and those aged 12-17 years in a 1:1:1:1:1 allocation (the higher option of Doses A-C or 290 µg)...
March 2024: Journal of Pediatric Gastroenterology and Nutrition
https://read.qxmd.com/read/38499632/creation-of-a-machine-learning-based-prognostic-prediction-model-for-various-subtypes-of-laryngeal-cancer
#11
JOURNAL ARTICLE
Wei Wang, Wenhui Wang, Dongdong Zhang, Peiji Zeng, Yue Wang, Min Lei, Yongjun Hong, Chengfu Cai
Depending on the source of the blastophore, there are various subtypes of laryngeal cancer, each with a unique metastatic risk and prognosis. The forecasting of their prognosis is a pressing issue that needs to be resolved. This study comprised 5953 patients with glottic carcinoma and 4465 individuals with non-glottic type (supraglottic and subglottic). Five clinicopathological characteristics of glottic and non-glottic carcinoma were screened using univariate and multivariate regression for CoxPH (Cox proportional hazards); for other models, 10 (glottic) and 11 (non-glottic) clinicopathological characteristics were selected using least absolute shrinkage and selection operator (LASSO) regression analysis, respectively; the corresponding survival models were established; and the best model was evaluated...
March 18, 2024: Scientific Reports
https://read.qxmd.com/read/38496183/a-narrative-review-on-the-viability-of-osteopathic-manipulative-medicine-in-treating-irritable-bowel-syndrome-with-constipation-ibs-c
#12
REVIEW
Mahi Basra, Hemangi Patel, Alison Stern-Harbutte, David Lee, Randal K Gregg, Holly B Waters, Anna K Potter
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by chronic abdominal pain and alterations in bowel habits, with global prevalence. The etiology of the disease is likely multifactorial; however, autonomic nervous system (ANS) dysfunction and immune-mediated inflammation may contribute the most to the hallmark symptoms of abdominal pain and altered motility of the gut. Current pharmacological therapies operate to modulate intestinal transit, alter the composition of the gut flora and control pain...
February 2024: Curēus
https://read.qxmd.com/read/38494933/paeoniflorin-alleviates-anxiety-and-visceral-hypersensitivity-via-hpa-axis-and-bdnf-trkb-plc%C3%AE-1-pathway-in-maternal-separation-induced-ibs-like-rats
#13
JOURNAL ARTICLE
Ruifeng Liang, Wenjing Ge, Xianmei Song, Huisen Wang, Weifeng Cui, Xuexia Zhang, Zheng Wei, Gengsheng Li
BACKGROUND: Irritable Bowel Syndrome (IBS) is a prevalent gastrointestinal disorder that significantly diminishes the quality of life for affected individuals. The pathophysiology of IBS remains poorly understood, and available therapeutic options for IBS are limited. The crucial roles of brain-gut interaction, which is mediated by the Hypothalamic-Pituitary-Adrenocortical (HPA) axis and the autonomic nervous system in IBS, have attracted increasing attention. OBJECTIVE: The objective of this study was to examine the impact of paeoniflorin (PF) on anxiety and visceral hypersensitivity in maternal separation-induced IBS-like rats...
March 15, 2024: Current Molecular Pharmacology
https://read.qxmd.com/read/38486305/italian-guidelines-for-the-management-of-irritable-bowel-syndrome-in-children-and-adolescents-joint-consensus-from-the-italian-societies-of-gastroenterology-hepatology-and-pediatric-nutrition-sigenp-pediatrics-sip-gastroenterology-and-endoscopy-sige-and-neurogastroenterology
#14
REVIEW
Giovanni Di Nardo, Giovanni Barbara, Osvaldo Borrelli, Cesare Cremon, Valentina Giorgio, Luigi Greco, Michele La Pietra, Giovanni Marasco, Licia Pensabene, Marisa Piccirillo, Claudio Romano, Silvia Salvatore, Michele Saviano, Vincenzo Stanghellini, Caterina Strisciuglio, Renato Tambucci, Rossella Turco, Letizia Zenzeri, Annamaria Staiano
The irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID), whose prevalence has widely increased in pediatric population during the past two decades. The exact pathophysiological mechanism underlying IBS is still uncertain, thus resulting in challenging diagnosis and management. Experts from 4 Italian Societies participated in a Delphi consensus, searching medical literature and voting process on 22 statements on both diagnosis and management of IBS in children. Recommendations and levels of evidence were evaluated according to the grading of recommendations, assessment, development, and evaluation (GRADE) criteria...
March 14, 2024: Italian Journal of Pediatrics
https://read.qxmd.com/read/38484117/nutritional-composition-and-therapeutic-potential-of-pineapple-peel-a-comprehensive-review
#15
JOURNAL ARTICLE
Arshad Farid, Mahrukh Mehraj, Susmita Das, Fathima Feroz, Ab Waheed Wani, S Q Dar, Sanjeev Kumar, Atif Khurshid Wani
Pineapple (Ananas comosus), the succulent and vibrant tropical fruit, is a symbol of exoticism and sweetness. The pineapple peel, often considered as waste, has garnered attention for its potential applications. The pineapple peel is rich in essential nutrients, including calcium, potassium, vitamin C, carbohydrates, dietary fiber, and water, making it beneficial for the digestive system, weight management, and overall balanced nutrition. It contains significant amounts of sugars such as sucrose, glucose, and fructose, along with citric acid as the predominant organic acid...
March 14, 2024: Chemistry & Biodiversity
https://read.qxmd.com/read/38483558/the-prediction-of-the-survival-in-patients-with-severe-trauma-during-prehospital-care-analyses-based-on-ntdb-database
#16
JOURNAL ARTICLE
Chi Peng, Liwei Peng, Fan Yang, Hang Yu, Qi Chen, Yibin Guo, Shuogui Xu, Zhichao Jin
PURPOSE: Traumas cause great casualties, accompanied by heavy economic burdens every year. The study aimed to use ML (machine learning) survival algorithms for predicting the 8-and 24-hour survival of severe traumas. METHODS: A retrospective study using data from National Trauma Data Bank (NTDB) was conducted. Four ML survival algorithms including survival tree (ST), random forest for survival (RFS) and gradient boosting machine (GBM), together with a Cox proportional hazard model (Cox), were utilized to develop the survival prediction models...
March 14, 2024: European Journal of Trauma and Emergency Surgery: Official Publication of the European Trauma Society
https://read.qxmd.com/read/38483304/healthcare-costs-of-irritable-bowel-syndrome-ibs-and-ibs-subtypes-in-the-united-states
#17
JOURNAL ARTICLE
Andrea Shin, Huiping Xu
BACKGROUND AIMS: Contemporaneous data on healthcare costs of irritable bowel syndrome (IBS) in the United States (U.S.) are lacking. We aimed to estimate all-cause and IBS-specific costs in patients with and without IBS and to compare costs across IBS subtypes. METHODS: Using Optum's de-identified Clinformatics® Data Mart Database (CDM), we performed a retrospective cohort analysis of patients with and without IBS using data spanning 2016-2021. IBS patients were identified by ICD-10 codes...
March 14, 2024: American Journal of Gastroenterology
https://read.qxmd.com/read/38431786/efficacy-of-mast-cell-directed-therapies-in-irritable-bowel-syndrome-a-systematic-review
#18
REVIEW
D Coppens, M Kips, T Stiévenard, C Mertens, H De Schepper
BACKGROUND AND STUDY AIM: Lately, mast cells (MCs) are increasingly implicated in the pathophysiology of irritable bowel syndrome (IBS). The aim of this systematic review was to assess the efficacy of mast cell directed therapies in reducing the main symptoms of IBS: abdominal pain and changes in stool frequency or consistency. PATIENTS AND METHODS: Pubmed, Web of Science and Scopus were searched until December 19, 2022. Trials evaluating the efficacy of mast cell directed therapies, compared to placebo or any form of control group, were included...
2024: Acta Gastro-enterologica Belgica
https://read.qxmd.com/read/38404960/raising-the-bar-in-the-management-of-ibs-c
#19
JOURNAL ARTICLE
Gregory S Sayuk
No abstract text is available yet for this article.
October 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/38404415/mechanism-of-action-considerations-in-the-management-of-ibs-c
#20
JOURNAL ARTICLE
Darren M Brenner
No abstract text is available yet for this article.
December 2023: Gastroenterology & Hepatology
keyword
keyword
101123
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.